PeptiDream Inc.
PeptiDream Inc.
Your view on PPTDF
Overview
What the company does, where it operates, and who runs it.
About PeptiDream Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Patrick Crawford Reid
- Headquarters
- 3-25-23 Tonomachi, Kawasaki, JP
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Patrick Crawford Reid
- Headquarters
- 3-25-23 Tonomachi, Kawasaki, JP
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides.
It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PeptiDream Inc., and the rating behind it. PPTDF last traded at $8.85; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PeptiDream Inc.. Starting points for PeptiDream Inc.: EPS -$28.20, beta 0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PeptiDream Inc.. PeptiDream Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PeptiDream Inc.. Trailing twelve-month EPS for PeptiDream Inc. stands at -$28.20. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PeptiDream Inc.. PeptiDream Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PeptiDream Inc. valued side by side against its closest peers. PeptiDream Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PeptiDream Inc., and how their positions are changing. At a $1.14B market value, institutional positions materially move PeptiDream Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PeptiDream Inc. executives and directors. Shares of PeptiDream Inc. have traded between $8.81 and $17.85 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PeptiDream Inc.. PeptiDream Inc. is a $1.14B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PeptiDream Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PeptiDream Inc.. Coverage tracks PeptiDream Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.